Lexiscan (regadenoson) / GE Healthcare, Astellas, Gilead 
Welcome,         Profile    Billing    Logout  
 50 Diseases   11 Trials   11 Trials   833 News 


123456789101112»
  • ||||||||||  Lexiscan (regadenoson) / GE Healthcare, Astellas, Gilead
    Review, Journal:  State of the art of CT myocardial perfusion. (Pubmed Central) -  Mar 12, 2025   
    CTP in addition to CCTA acquisition shows good diagnostic accuracy compared to invasive fractional flow reserve (FFR). Furthermore, the evaluation of late iodine enhancement (LIE) could be performed allowing the detection of myocardial infarction.
  • ||||||||||  Lexiscan (regadenoson) / GE Healthcare, Astellas, Gilead
    Fully Quantitative Cardiovascular Magnetic Resonance Myocardial Perfusion for Detection of Cardiac Allograft Vasculopathy (Poster Hall) -  Jan 19, 2025 - Abstract #ISHLT2025ISHLT_261;    
    Quantitative short-axis perfusion maps were acquired using single bolus of gadolinium contrast (0.05 mmol/kg), dual sequence perfusion imaging at rest and during stress using adenosine or regadenosone vasodilation...The MP at rest, stress and MPR in the respective groups are shown in Figure 1. The MPR could discriminate CAV2-3 (ROC AUC 0.82, 95% CI[0.69-0.96]) and using a cutoff of 2.2 the sensitivity was 100%, specificity was 69%, positive and negative predictive value was 17% and100%.Conclusion In this multi-center retrospective study MPR assessed by CMR could discriminate CAV2-3 with both high sensitivity and negative predictive value.
  • ||||||||||  Lexiscan (regadenoson) / GE Healthcare, Astellas, Gilead
    Journal:  REGADENOSON MYOCARDIAL PERFUSION SCINTIGRAPHY: A SINGLE CENTRE EXPERIENCE. (Pubmed Central) -  Dec 3, 2024   
    The MPR could discriminate CAV2-3 (ROC AUC 0.82, 95% CI[0.69-0.96]) and using a cutoff of 2.2 the sensitivity was 100%, specificity was 69%, positive and negative predictive value was 17% and100%.Conclusion In this multi-center retrospective study MPR assessed by CMR could discriminate CAV2-3 with both high sensitivity and negative predictive value. Regadenoson is associated with transient haemodynamic changes and non-serious transient adverse effects.
  • ||||||||||  Lexiscan (regadenoson) / GE Healthcare, Astellas, Gilead
    First experiences with 18F-Flurpiridaz in clinical practice (Hall G2) -  Sep 27, 2024 - Abstract #EANM2024EANM_1416;    
    Further validation of this technique is mandatory and will be helpful to introduce this technique into clinical practice. All stress imaging was done using pharmacological stress with either adenosine (140
  • ||||||||||  Lexiscan (regadenoson) / GE Healthcare, Astellas, Gilead
    Feasibility of right ventricular imaging with F18 Flurpiridaz positron emission tomography (Hall F) -  Sep 27, 2024 - Abstract #EANM2024EANM_1098;    
    Materials and Thirteen patients (4w, 9m) underwent routine one-day rest and regadenoson stress F18 Flurpiridaz PET for the workup of suspected or known coronary artery disease (injected dose: 121 MBq (IQR: 108-130) for rest, 227 MBq (IQR: 201-260) for stress)... RV analysis seems feasible with F18 Flurpidaz PET perfusion imaging, but should be tested in larger patient cohorts using independent validation and optimized acquisition and analysis techniques.
  • ||||||||||  Lexiscan (regadenoson) / GE Healthcare, Astellas, Gilead
    Journal:  Adenosine 2A Receptor Agonism Improves Survival in Extracorporeal Cardiopulmonary Resuscitation. (Pubmed Central) -  Sep 26, 2024   
    Consistency in the application of flushing is recommended. In a model of cardiac arrest treated with ECPR, A2AR agonism increased survival at 24 h and reduced neurologic damage suggesting A2AR activation may be a promising therapeutic target after cardiac arrest.
  • ||||||||||  Lexiscan (regadenoson) / GE Healthcare, Astellas, Gilead, Opdivo (nivolumab) / BMS, Yervoy (ipilimumab) / BMS
    IMMUNE CHECKPOINT INHIBITOR-INDUCED NONINFLAMMATORY CARDIOMYOPATHY (Convention Center Exhibit Hall: Poster Area 1) -  Sep 11, 2024 - Abstract #CHEST2024CHEST_6969;    
    As ICIs become increasingly integral to cancer therapy, our findings underscore the importance of vigilant cardiovascular monitoring and early intervention. Future research should delve into the mechanisms and prevention of ICI-induced noninflammatory cardiomyopathy.
  • ||||||||||  Lexiscan (regadenoson) / GE Healthcare, Astellas, Gilead
    Trial completion:  Regadenoson Infusion of Marginalized Donor Lungs in an EVLP System (clinicaltrials.gov) -  Aug 4, 2024   
    P1,  N=47, Completed, 
    Future research should delve into the mechanisms and prevention of ICI-induced noninflammatory cardiomyopathy. Recruiting --> Completed
  • ||||||||||  Lexiscan (regadenoson) / GE Healthcare, Astellas, Gilead
    CASE OF PULMONARY ARTERY RUPTURE AND ONE LUNG VENTILATION (Convention Center Exhibit Hall: Poster Area 1) -  Jul 31, 2024 - Abstract #CHEST2024CHEST_2492;    
    A multi-disciplinary approach is essential and careful balanced decision between a conservative, interventional and surgical approach should be made. Despite having no specific guidelines for management of PA rupture, timely endovascular intervention and securing unaffected lung has promising results and early recovery.
  • ||||||||||  Lexiscan (regadenoson) / GE Healthcare, Astellas, Gilead
    PULSES AND PUZZLES: REGADENOSON'S CURIOUS ENCOUNTER WITH LEFT BUNDLE BRANCH BLOCK IN MYOCARDIAL PERFUSION IMAGING (Convention Center Exhibit Hall: Poster Area 1) -  Jul 31, 2024 - Abstract #CHEST2024CHEST_2459;    
    INTRODUCTION: Myocardial perfusion imaging (MPI) stress test is conducted utilizing exercise or vasodilatory agents such as dipyridamole, which achieves vasodilation by inhibiting adenosine deaminase and phosphodiesterase, or Regadenoson, which enhances coronary blood flow by acting as an adenosine receptor agonist, thus simulating the effects of exercise. While the exact mechanism of LBBB induced by regadenoson remains unclear, physicians should uphold clinical vigilance to exclude obstructive coronary artery disease through coronary angiography.
  • ||||||||||  Lexiscan (regadenoson) / GE Healthcare, Astellas, Gilead
    Trial completion:  Accuracy of an Echo-Stress Protocol Using Regadenoson With Speckle Tracking (clinicaltrials.gov) -  Jul 3, 2024   
    P4,  N=300, Completed, 
    While the exact mechanism of LBBB induced by regadenoson remains unclear, physicians should uphold clinical vigilance to exclude obstructive coronary artery disease through coronary angiography. Active, not recruiting --> Completed
  • ||||||||||  Lexiscan (regadenoson) / GE Healthcare, Astellas, Gilead
    Trial completion, Enrollment change:  Microvascular Blood Flow in Sickle Cell Anemia (clinicaltrials.gov) -  Jun 25, 2024   
    P=N/A,  N=91, Completed, 
    Regadenoson-induced global hyperemic MBF was lower in OB than in NW (1.88 Active, not recruiting --> Completed | N=200 --> 91
  • ||||||||||  Lexiscan (regadenoson) / GE Healthcare, Astellas, Gilead
    Journal:  How to Assess Non-Responsiveness to Vasodilator Stress. (Pubmed Central) -  Jun 16, 2024   
    Quantitative MFR values of 1-1.2 should raise the suspicion for non-responsiveness in the setting of normal perfusion, along with the absence of splenic switch off. Newer metrics such as splenic response ratio can be used to aid identification of potential non-responders to pharmacologic vasodilators.
  • ||||||||||  Lexiscan (regadenoson) / GE Healthcare, Astellas, Gilead
    Preclinical, Journal:  The adenosine A2A receptor in human sperm: its role in sperm motility and association with in vitro fertilization outcomes. (Pubmed Central) -  Jun 14, 2024   
    The functional role of A2AR in sperm was assessed by incubating human sperm with an A2AR agonist (regadenoson) and an A2AR antagonist (SCH58261)...Furthermore, the fertilization rate during IVF was lower in men with decreased sperm level of A2AR than in men with normal sperm level of A2AR. These results indicate that A2AR is important for human sperm motility and is associated with IVF outcome.
  • ||||||||||  Lexiscan (regadenoson) / GE Healthcare, Astellas, Gilead
    Regadenoson stress echocardiography: a road ahead (Station 8 - Research Gateway) -  May 14, 2024 - Abstract #ESC2024ESC_2319;    
    Regadenoson SE showed to be both safe in assessing ischemic cardiomyopathy and very useful for its prognostic value. These findings encourage its expanding use in the stress echo lab.
  • ||||||||||  Lexiscan (regadenoson) / GE Healthcare, Astellas, Gilead
    Trial completion date, Trial primary completion date:  Allograft Dysfunction in Heart Transplant (clinicaltrials.gov) -  May 8, 2024   
    P4,  N=376, Recruiting, 
    These findings encourage its expanding use in the stress echo lab. Trial completion date: Apr 2024 --> Dec 2024 | Trial primary completion date: Apr 2024 --> Dec 2024
  • ||||||||||  Lexiscan (regadenoson) / GE Healthcare, Astellas, Gilead
    Stress Testing: Symptom-limited Stress and Regadenoson Reversal (713AB (Convention Center); In-Person) -  Apr 26, 2024 - Abstract #SNMMI2024SNMMI_338;    
    Trial completion date: Apr 2024 --> Dec 2024 | Trial primary completion date: Apr 2024 --> Dec 2024 Sponsored by SNMMI Technologist Section
  • ||||||||||  Lexiscan (regadenoson) / GE Healthcare, Astellas, Gilead
    Journal:  Downward myocardial creep during stress PET imaging is inversely associated with mortality. (Pubmed Central) -  Apr 24, 2024   
    Downward myocardial creep during regadenoson stress carries additional information for the prediction of ACM beyond conventional flow and perfusion PET-MPI. This novel imaging biomarker is quantified automatically and rapidly from stress dynamic PET-MPI.
  • ||||||||||  Lexiscan (regadenoson) / GE Healthcare, Astellas, Gilead
    Trial completion date, Trial primary completion date:  The MATCH Investigation: CT Myocardial Perfusion and CT-FFR vs PET MPI (clinicaltrials.gov) -  Apr 14, 2024   
    P=N/A,  N=20, Recruiting, 
    This novel imaging biomarker is quantified automatically and rapidly from stress dynamic PET-MPI. Trial completion date: Apr 2024 --> Dec 2024 | Trial primary completion date: Apr 2024 --> Dec 2024
  • ||||||||||  Lexiscan (regadenoson) / GE Healthcare, Astellas, Gilead
    Trial completion date, Trial primary completion date:  Improvement Assessment of Coronary Flow Dysfunction Using Fundamental Fluid Dynamics (clinicaltrials.gov) -  Mar 2, 2024   
    P=N/A,  N=68, Active, not recruiting, 
    Trial completion date: Apr 2024 --> Dec 2024 | Trial primary completion date: Apr 2024 --> Dec 2024 Trial completion date: Jun 2023 --> Jun 2024 | Trial primary completion date: Jun 2023 --> Jun 2024
  • ||||||||||  Lexiscan (regadenoson) / GE Healthcare, Astellas, Gilead
    Enrollment change, Trial completion date, Trial primary completion date:  The MATCH Investigation: CT Myocardial Perfusion and CT-FFR vs PET MPI (clinicaltrials.gov) -  Feb 15, 2024   
    P=N/A,  N=20, Recruiting, 
    Trial completion date: Jun 2023 --> Jun 2024 | Trial primary completion date: Jun 2023 --> Jun 2024 N=30 --> 20 | Trial completion date: Sep 2023 --> Apr 2024 | Trial primary completion date: Sep 2023 --> Apr 2024
  • ||||||||||  Lexiscan (regadenoson) / GE Healthcare, Astellas, Gilead
    CARDIOPHYLAXIS: KOUNIS SYNDROME TYPE II INDUCED BY REGADENOSON IN A PATIENT WITH SYSTEMIC MASTOCYTOSIS (Hall B4-5) -  Jan 26, 2024 - Abstract #ACC2024ACC_6781;    
    His chest pain was resolved with sublingual nitroglycerin, however, emergent left heart catheterization revealed 80% calcified stenosis of the mid-right coronary artery (mRCA). Systemic mastocytosis is a challenging comorbidity in patients with coronary artery disease that limits the use of antiplatelet therapy and can present as Kounis syndrome.
  • ||||||||||  Lexiscan (regadenoson) / GE Healthcare, Astellas, Gilead
    LACK OF HEMODYNAMIC RESPONSE TO VASODILATOR STRESS IS ASSOCIATED WITH CARDIOVASCULAR EVENTS (Moderated Poster Theater 07) -  Jan 26, 2024 - Abstract #ACC2024ACC_6407;    
    Abnormal perfusion was defined as stress total perfusion deficit (sTPD)?5%, HR response as increase ?10bpm with stress, and systolic BP response as decrease ?10mmHg with stress. Of 22,494 patients (stress with regadenoson 44%, dipyridamole 44%, adenosine 12%), 4,606 (20.5%) had MACE in 3.7
  • ||||||||||  Lexiscan (regadenoson) / GE Healthcare, Astellas, Gilead
    DECIPHERING CHEST PAIN IN RECONSTRUCTED HEART (Hall B4-5) -  Jan 26, 2024 - Abstract #ACC2024ACC_4881;    
    SVG-PA poses clinical dilemma, specially in non-surgical candidates. Continued research is vital for optimizing management.
  • ||||||||||  Lexiscan (regadenoson) / GE Healthcare, Astellas, Gilead
    A RARE CASE OF LARGE CORONARY ARTERY TO PULMONARY ARTERY FISTULA (Hall B4-5) -  Jan 26, 2024 - Abstract #ACC2024ACC_4056;    
    Such fistulas can cause relatively low perfusion pressures, and carry blood with low oxygen saturation, reflecting the pulmonary artery source. In the presence of collateral circulation from a normally arising coronary artery, coronary artery steal is noted as flow is directed from the normal coronary artery to the pulmonary artery via collateral vessels.
  • ||||||||||  Lexiscan (regadenoson) / GE Healthcare, Astellas, Gilead
    Journal:  Role of the clinical radiopharmacist in patient safety during myocardial perfusion imaging with vasodilator stress agents. (Pubmed Central) -  Jan 7, 2024   
    Working in a systematic way, the radiopharmacist was able to detect a high number of issues related to regadenoson, with one out of four patients presenting some clinical contraindication. The recommendations given by the radiopharmacist were well accepted by the nuclear physicians who changed their approach contributing to increase the safety of patients referred for MPI.
  • ||||||||||  Lexiscan (regadenoson) / GE Healthcare, Astellas, Gilead
    Journal, Metastases:  Regadenoson Reduces Soluble Receptor for Advanced Glycation End-Products in Lung Recipients. (Pubmed Central) -  Nov 27, 2023   
    In vivo and in vitro studies suggest that A2AR activation reduces sRAGE in part by inhibiting MMP-9 production by monocytes/macrophages. These results suggest a novel molecular mechanism by which A2AR agonists reduces primary graft dysfunction.